These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 25751579)
41. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides. Bowman MJ; Chmielewski J Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162 [TBL] [Abstract][Full Text] [Related]
42. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses. Arodola OA; Soliman ME Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167 [TBL] [Abstract][Full Text] [Related]
43. Perspectives in HIV protease inhibitors. Leonard JM Adv Exp Med Biol; 1996; 394():319-25. PubMed ID: 8815696 [No Abstract] [Full Text] [Related]
44. Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases. De Voss JJ; Sui Z; DeCamp DL; Salto R; Babé LM; Craik CS; Ortiz de Montellano PR J Med Chem; 1994 Mar; 37(5):665-73. PubMed ID: 8126707 [TBL] [Abstract][Full Text] [Related]
45. HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols. Budt KH; Peyman A; Hansen J; Knolle J; Meichsner C; Paessens A; Ruppert D; Stowasser B Bioorg Med Chem; 1995 May; 3(5):559-71. PubMed ID: 7648204 [TBL] [Abstract][Full Text] [Related]
46. Structure-based inhibition of HIV-1 protease activity and viral infectivity. DeCamp DL; Babé LM; Furth P; Ortiz de Montellano P; Kuntz ID; Craik CS Adv Exp Med Biol; 1991; 306():489-92. PubMed ID: 1812747 [No Abstract] [Full Text] [Related]
47. HIV-1 protease: maturation, enzyme specificity, and drug resistance. Louis JM; Weber IT; Tözsér J; Clore GM; Gronenborn AM Adv Pharmacol; 2000; 49():111-46. PubMed ID: 11013762 [No Abstract] [Full Text] [Related]
48. Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase. Konvalinka J; Litera J; Weber J; Vondrásek J; Hradílek M; Soucek M; Pichová I; Majer P; Strop P; Sedlácek J; Heuser AM; Kottler H; Kräusslich HG Eur J Biochem; 1997 Dec; 250(2):559-66. PubMed ID: 9428710 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation. Humpolíčková J; Weber J; Starková J; Mašínová E; Günterová J; Flaisigová I; Konvalinka J; Majerová T Sci Rep; 2018 Jul; 8(1):10438. PubMed ID: 29992979 [TBL] [Abstract][Full Text] [Related]
50. Nanopore detects γ-radiation inhibited HIV-1 protease activity. Li M; Li W; Xiao Y; Liu Q; Liang L; Wang D; Huang W; Wang L Biosens Bioelectron; 2021 Dec; 194():113602. PubMed ID: 34481241 [TBL] [Abstract][Full Text] [Related]
51. Chemical methods for degradation of target proteins using designed light-activatable organic molecules. Tanimoto S; Takahashi D; Toshima K Chem Commun (Camb); 2012 Aug; 48(62):7659-71. PubMed ID: 22739361 [TBL] [Abstract][Full Text] [Related]
52. Strategies to inhibit viral polyprotein cleavages. Korant BD Ann N Y Acad Sci; 1990; 616():252-7. PubMed ID: 2078022 [No Abstract] [Full Text] [Related]
53. Retroviral proteases and their roles in virion maturation. Konvalinka J; Kräusslich HG; Müller B Virology; 2015 May; 479-480():403-17. PubMed ID: 25816761 [TBL] [Abstract][Full Text] [Related]
54. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022 [TBL] [Abstract][Full Text] [Related]
55. Structural and biochemical characterization of a novel aminopeptidase from human intestine. Tykvart J; Bařinka C; Svoboda M; Navrátil V; Souček R; Hubálek M; Hradilek M; Šácha P; Lubkowski J; Konvalinka J J Biol Chem; 2015 May; 290(18):11321-36. PubMed ID: 25752612 [TBL] [Abstract][Full Text] [Related]
56. MAS NMR of HIV-1 protein assemblies. Suiter CL; Quinn CM; Lu M; Hou G; Zhang H; Polenova T J Magn Reson; 2015 Apr; 253():10-22. PubMed ID: 25797001 [TBL] [Abstract][Full Text] [Related]
57. Inhibitor and substrate binding induced stability of HIV-1 protease against sequential dissociation and unfolding revealed by high pressure spectroscopy and kinetics. Ingr M; Lange R; Halabalová V; Yehya A; Hrnčiřík J; Chevalier-Lucia D; Palmade L; Blayo C; Konvalinka J; Dumay E PLoS One; 2015; 10(3):e0119099. PubMed ID: 25781460 [TBL] [Abstract][Full Text] [Related]
58. Functional label-free assays for characterizing the in vitro mechanism of action of small molecule modulators of capsid assembly. Lad L; Clancy S; Koditek D; Wong MH; Jin D; Niedziela-Majka A; Papalia GA; Hung M; Yant S; Somoza JR; Hu E; Chou C; Tse W; Halcomb R; Sakowicz R; Pagratis N Biochemistry; 2015 Apr; 54(13):2240-8. PubMed ID: 25774576 [TBL] [Abstract][Full Text] [Related]
59. A myristoyl switch at the plasma membrane triggers cleavage and oligomerization of Mason-Pfizer monkey virus matrix protein. Častorálová M; Sýs J; Prchal J; Pavlů A; Prokopová L; Briki Z; Hubálek M; Ruml T Elife; 2024 Mar; 13():. PubMed ID: 38517277 [TBL] [Abstract][Full Text] [Related]
60. Neutral sphingomyelinase 2 is required for HIV-1 maturation. Waheed AA; Zhu Y; Agostino E; Naing L; Hikichi Y; Soheilian F; Yoo SW; Song Y; Zhang P; Slusher BS; Haughey NJ; Freed EO Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2219475120. PubMed ID: 37406093 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]